Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses

(2011) Thomas Krausgruber et al.   NATURE IMMUNOLOGY

Determinants of interferon β efficacy in patients with multiple sclerosis

(2011) Joep Killestein et al.   Nature Reviews Neurology

Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis

(2010) Konstantin E. Balashov et al.   ANNALS OF NEUROLOGY

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

(2010) P. Serrano-Fernández et al.   AUTOIMMUNITY

Single-Nucleotide Polymorphisms in Response to Interferon-Beta Therapy in Multiple Sclerosis

(2010) Koen Vandenbroeck et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Natalizumab treatment reduces endothelial activity in MS patients

(2010) Alban Millonig et al.   JOURNAL OF NEUROIMMUNOLOGY

APOE  4 and Cognitive Dysfunction in Multiple Sclerosis: A Review

(2010) O. Ghaffar et al.   JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-β1b

(2010) JS Alexander et al.   Multiple Sclerosis Journal

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands

(2010) I. Bosca et al.   Multiple Sclerosis Journal

Influencia del polimorfismo del gen de la APOE en la respuesta al tratamiento con interferón beta en esclerosis múltiple

(2010) A.L. Guerrero et al.   NEUROLOGIA

APOE  4 and the cognitive genetics of multiple sclerosis

(2010) O. Ghaffar et al.   NEUROLOGY

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS

(2010) Robert H Goertsches et al.   PHARMACOGENOMICS

IFN-β pharmacogenomics in multiple sclerosis

(2010) Koen Vandenbroeck et al.   PHARMACOGENOMICS

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis

(2010) Kaushal S. Gandhi et al.   PLoS One

Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis

(2009) Manuel Comabella et al.   ARCHIVES OF NEUROLOGY

MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients

(2009) R. Alvarez-Lafuente et al.   EUROPEAN JOURNAL OF NEUROLOGY

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of IFN-ß therapy on the frequency and function of CD4+CD25+ regulatory T cells and Foxp3 gene expression in relapsing–remitting multiple sclerosis (RRMS): A preliminary study

(2009) Afshin Namdar et al.   JOURNAL OF NEUROIMMUNOLOGY

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

(2009) F. Patti et al.   Multiple Sclerosis Journal

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

(2009) Philip L De Jager et al.   NATURE GENETICS

Treatment of multiple sclerosis: role of natalizumab

(2009) Giancarlo Comi   NEUROLOGICAL SCIENCES

Multiple sclerosis pharmacogenomics: Maximizing efficacy of therapy

(2009) D. J. Pappas et al.   NEUROLOGY

Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients

(2009) Catherine O’Doherty et al.   PHARMACOGENOMICS

Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis

(2008) Esther Byun et al.   ARCHIVES OF NEUROLOGY

Pharmacogenomics of multiple sclerosis: in search for a personalized therapy

(2008) Iván Martinez-Forero et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen

(2008) Koen Vandenbroeck et al.   PHARMACOGENOMICS

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

(2008) Lisa G. M. van Baarsen et al.   PLoS One